Abstract
BackgroundSurvival in cutaneous melanoma (CM) is heterogeneous. Loss in life expectancy (LLE) measures impact of CM on remaining lifespan compared to general population. ObjectivesInvestigating LLE in operated stage II-III CM patients. MethodsData from 8,061 patients (aged 40-80 years) with stage II–III CM in Sweden, diagnosed between 2005-2018 were analyzed (Swedish Melanoma Registry). A flexible parametric survival model estimated life expectancy and LLE. ResultsBased on 2018 diagnoses, stage II and III CM patients lost 2209 and 1902 life years, respectively. LLE was higher in stage III: 5.2 vs 10.9 years (stage II vs III 60-year-old females). Younger patients had higher LLE: 10.7 vs 3.9 years (stage II CM in 40 vs 70-year-old males). In stage II, females had lower LLE than males; 50-year-old females and males stage II CM had LLE equal to 7.3 and 8.3 years, respectively. LLE increased with higher substages, stage IIB resembling IIIB and IIC resembling IIIC-D. LimitationsExtrapolation was used to estimate LLE. Varying stage group sizes require caution. ConclusionsOur results are both clinically relevant and easy-to-interpret measures of the impact of CM on survival, but the results also summarize the prognosis over the lifetime of a CM patient.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
